Nonalcoholic fatty liver disease and vascular function: cross-sectional analysis in the Framingham heart study
- PMID: 25745056
- PMCID: PMC4520415
- DOI: 10.1161/ATVBAHA.114.305200
Nonalcoholic fatty liver disease and vascular function: cross-sectional analysis in the Framingham heart study
Abstract
Objective: Patients with nonalcoholic fatty liver disease (NAFLD) have an increased risk of cardiovascular disease; however, it is not known whether NAFLD contributes to cardiovascular disease independent of established risk factors. We examined the association between NAFLD and vascular function.
Approach and results: We conducted a cross-sectional study of 2284 Framingham Heart Study participants without overt cardiovascular disease who had liver fat attenuation measured on computed tomography and who had measurements of vascular function and covariates. We evaluated the association between NAFLD and vascular function using multivariable partial correlations adjusting for age, sex, cohort, smoking, diabetes mellitus, hyperlipidemia, hypertension, body mass index, and visceral adipose tissue. The prevalence of NAFLD in our sample (mean age, 52±12 years; 51.4% women) was 15.3%. In age-, sex-, and cohort-adjusted analyses, greater liver fat was modestly associated with lower flow-mediated dilation (r=-0.05; P=0.02), lower peripheral arterial tonometry ratio (r=-0.20; P<0.0001), higher carotid-femoral pulse wave velocity (r=0.13; P<0.0001), and higher mean arterial pressure (r=0.11; P<0.0001). In multivariable-adjusted models, NAFLD remained associated with higher mean arterial pressure (r=0.06; P=0.005) and lower peripheral arterial tonometry ratio (r=-0.12; P<0.0001). The association between NAFLD and peripheral arterial tonometry ratio persisted after further adjustment for body mass index and visceral adipose tissue.
Conclusions: For multiple measures of vascular function, the relationship with NAFLD appeared largely determined by shared cardiometabolic risk factors. The persistent relationship with reduced peripheral arterial tonometry response beyond established risk factors suggests that NAFLD may contribute to microvascular dysfunction.
Keywords: multidetector computed tomography; obesity; risk factors; vascular endothelium.
© 2015 American Heart Association, Inc.
Figures
Similar articles
-
Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study.Cardiovasc Diabetol. 2018 Feb 16;17(1):28. doi: 10.1186/s12933-018-0670-7. Cardiovasc Diabetol. 2018. PMID: 29452601 Free PMC article.
-
Association of Nonalcoholic Fatty Liver Disease With Lower Brain Volume in Healthy Middle-aged Adults in the Framingham Study.JAMA Neurol. 2018 Jan 1;75(1):97-104. doi: 10.1001/jamaneurol.2017.3229. JAMA Neurol. 2018. PMID: 29159396 Free PMC article.
-
Increased arterial stiffness in nonalcoholic fatty liver disease: a systematic review and meta-analysis.Eur J Gastroenterol Hepatol. 2017 Sep;29(9):e28-e35. doi: 10.1097/MEG.0000000000000909. Eur J Gastroenterol Hepatol. 2017. PMID: 28542113 Review.
-
Endothelial function, arterial stiffness and adherence to the 2010 Dietary Guidelines for Americans: a cross-sectional analysis.Br J Nutr. 2015 Jun 14;113(11):1773-81. doi: 10.1017/S0007114515000859. Epub 2015 Apr 17. Br J Nutr. 2015. PMID: 25885520 Free PMC article.
-
Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis.Eur J Gastroenterol Hepatol. 2018 Jun;30(6):631-636. doi: 10.1097/MEG.0000000000001075. Eur J Gastroenterol Hepatol. 2018. PMID: 29351115 Review.
Cited by
-
Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis.BMC Med. 2024 Mar 6;22(1):101. doi: 10.1186/s12916-024-03315-0. BMC Med. 2024. PMID: 38448943 Free PMC article.
-
A discrete choice experiment to elicit preferences for a liver screening programme in Queensland, Australia: a mixed methods study to select attributes and levels.BMC Health Serv Res. 2023 Sep 5;23(1):950. doi: 10.1186/s12913-023-09934-2. BMC Health Serv Res. 2023. PMID: 37670274 Free PMC article.
-
Risk of dementia or cognitive impairment in non-alcoholic fatty liver disease: A systematic review and meta-analysis.Front Aging Neurosci. 2022 Sep 20;14:985109. doi: 10.3389/fnagi.2022.985109. eCollection 2022. Front Aging Neurosci. 2022. PMID: 36204558 Free PMC article.
-
Severity of Nonalcoholic Fatty Liver Disease is Associated With Cardiovascular Outcomes in Patients With Prehypertension or Hypertension: A Community-Based Cohort Study.Front Endocrinol (Lausanne). 2022 Aug 25;13:942647. doi: 10.3389/fendo.2022.942647. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36093080 Free PMC article.
-
Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review.Cells. 2022 Aug 12;11(16):2511. doi: 10.3390/cells11162511. Cells. 2022. PMID: 36010588 Free PMC article. Review.
References
-
- Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Changes in the prevalence of the most common causes of chronic liver diseases in the united states from 1988 to 2008. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2011;9:524–530. e521. quiz e560. - PubMed
-
- Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Alimentary pharmacology & therapeutics. 2011;34:274–285. - PubMed
-
- Arase Y, Suzuki F, Ikeda K, Kumada H, Tsuji H, Kobayashi T. Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease. Journal of gastroenterology. 2009;44:1064–1070. - PubMed
Publication types
MeSH terms
Grants and funding
- N01-HC-25195/HC/NHLBI NIH HHS/United States
- HL107385/HL/NHLBI NIH HHS/United States
- R01 HL107385/HL/NHLBI NIH HHS/United States
- N01 HC025195/HC/NHLBI NIH HHS/United States
- R01 HL076784/HL/NHLBI NIH HHS/United States
- R01 HL060040/HL/NHLBI NIH HHS/United States
- HL077447/HL/NHLBI NIH HHS/United States
- R01 HL077447/HL/NHLBI NIH HHS/United States
- UL1 TR000157/TR/NCATS NIH HHS/United States
- R01 AG047645/AG/NIA NIH HHS/United States
- UL1-TR000157/TR/NCATS NIH HHS/United States
- R01 HL115391/HL/NHLBI NIH HHS/United States
- HL70100/HL/NHLBI NIH HHS/United States
- HL102299/HL/NHLBI NIH HHS/United States
- HL076784/HL/NHLBI NIH HHS/United States
- R01 HL102299/HL/NHLBI NIH HHS/United States
- 1R01HL60040/HL/NHLBI NIH HHS/United States
- N01HC25195/HL/NHLBI NIH HHS/United States
- K24 HL113128/HL/NHLBI NIH HHS/United States
- R01 HL070100/HL/NHLBI NIH HHS/United States
- K23DK08145/DK/NIDDK NIH HHS/United States
- R01AG047645-1/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
